ATG16L1 and Crohn disease: While the protective mechanisms triggered by γδ IEL-secreted API5 remains to be determined, and the safety of the long-term injection of API5 in mice and humans must be carefully considered, this study demonstrates that API5 constitutes a prime therapeutic target for Crohn’s disease in the context of ATG16L1 deficiency.